Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Cowen Health Care Conference Transcript

Mar 08, 2023 / 07:10PM GMT
Release Date Price: $190.41 (-2.02%)
Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst

Thank you everyone for joining us for the Alnylam Pharmaceuticals Fireside Chat at the 43rd Annual TD Cowen Conference. I'm covering analyst, Ritu Baral, and with us today from Alnylam, we have Pushkal Garg, CMO; as well as Rena Denoncourt, VP and TTR program lead at Alnylam. Welcome Rena and Pushkal. Good to have you back.

Rena N. Denoncourt
Alnylam Pharmaceuticals, Inc. - VP & TTR Franchise Lead

Thank you.

Pushkal P. Garg
Alnylam Pharmaceuticals, Inc. - Chief Medical Officer and Executive VP of Development & Medical Affairs

Thank you.

Questions & Answers

Ritu Subhalaksmi Baral
TD Cowen, Research Division - MD & Senior Biotechnology Analyst

All right, let's start with your sNDA. You know where I'm going with this. Have you had any more recent communication with the FDA about the sNDA for ATTR-CM? Have you been notified of any emerging review issues? You

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot